

September 15, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block-G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Undertaking that the Proposed Scheme is yet to be executed

Ref: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the proposed Scheme of Arrangement in the nature of amalgamation of M/s Chemgenix Laboratories Private Limited ("CLPL" or "Transferor Company") and M/s Vilin Bio Med Limited ("VBML" or "Transferee Company") and their respective Shareholders and Creditors under Sections 230 to 232 of the Companies Act, 2013 read with applicable rules made thereunder ("Scheme")

Dear Sir / Madam,

With reference to the aforesaid subject and captioned reference, we would like to inform you that the proposed Scheme of arrangement in the nature of Merger/Amalgamation of M/s Chemgenix Laboratories Private Limited ("CLPL" or "Transferor Company") and M/s Vilin Bio Med Limited ("VBML" or "Transferee Company") and their respective Shareholders and Creditors is being complied in accordance with the directions of the NCLT Order dated September 10, 2026.

Further, pursuant to obtaining the said In-Principle Approval, CLPL and VBML shall make an application to Hon'ble National Company Law Tribunal ("NCLT") for their approval and after complying with all the provisions of the Companies Act, 2013 and the terms of approval by NSE and Hon'ble NCLT as may be prescribed, the Company shall execute the Scheme by giving effect to the terms of the Scheme.

Kindly take the above information on record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260